Statistics

Total Visits

Views
A Phase IIb Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) Versus Placebo in Combination With Background Methotrexate in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone20

Select a period of time:

Number of views in the range

Views
A Phase IIb Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) Versus Placebo in Combination With Background Methotrexate in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone8

Views

Views
December 20231
January 20241
February 20241
March 20241
April 20240
May 20244
June 20240
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States8
 

Top cities views

Views
Boardman2
Ashburn1
Chicago1